Description
Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Almotriptan does not prevent migraine attacks.
Top Gene Interactions
Related Pathways
General Information
- Metabolism: Hepatic. Route of Elimination: Almotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized. Half Life: 3-4 hours
- Uses/Sources: Almotriptan is indicated for the acute treatment of migraine with or without aura in adults. [Wikipedia]
- Symptoms: Nausea, drowsiness, dizziness, diarrhea, headache, sweating, or dry mouth may occur.
- Treatment: Gastrointestinal decontamination (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with Almotriptan. Clinical and electrocardiographic monitoring should be continued for at least 20 hours, even if clinical symptoms are not observed. (L1712)
- Route of Exposure: Oral
Mechanism of Action
Target Name | Mechanism of Action | References |
---|---|---|
5-hydroxytryptamine receptor 1B 5-hydroxytryptamine receptor 1D |
Almotriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction. |
11050304 11752352 10824628 11069595 11642004 11134654 10193663 |
Almotriptan Interacts with Diseases
Disease | Inference Score | References/Inference Genes |
Autism | 8.95 |
|
Occupational Diseases | 8.47 |
|
Chronic obstructive pulmonary disease | 7.71 |
|
Amphetamine-Related Disorders | 7.42 | |
Acute lymphoblastic leukemia | 7.27 |
|
Hypotension | 7.01 |
|
Lung Injury | 6.88 |
|
Prostatic Neoplasms | 6.53 |
|
Brunner Syndrome | 6.47 |
|
Parkinson's disease | 6.42 |
|
Drug Metabolism, Poor, CYP2C19-Related | 6.38 | |
Drug Metabolism, Poor, CYP2D6-Related | 6.29 | |
Trimethylaminuria | 6.26 |
|
Breast carcinoma | 6.08 |
|
Prenatal Exposure Delayed Effects | 6.05 |
|
Fetal Nutrition Disorders | 5.92 |
|
Antisocial Personality Disorder | 5.66 |
|
Primary ovarian insufficiency | 5.18 |
|
Obsessive-compulsive disorder | 5.15 |
|
Adenomatous Polyposis Coli | 5.13 |
|